naion with semaglutide May Raise Risk for NAION, Does Not Impact Risk for DR Semaglutide use in patients with

All the patients using GLP-1RAs in the study had been prescribed them for type 2 diabetes management, not to treat obesity

The best choice depends on your symptoms, your medical history, and how your body responds to treatment

The use of antipsychotics may result in many unwanted side-effects, such as involuntary movement disorders, gynecomastia, impotence, weight-gain and metabolic syndrome

Single-Nucleotide Polymorphism Rs7754840 of CDKAL1 Is Associated with Impaired Insulin Secretion in Nondiabetic Offspring of Type 2 Diabetic Subjects and in a Large Sample of Men with Normal Glucose Tolerance. Vettorazzi, Jean Franciesco, Mirian Ayumi Kurauti, et al

Published Phase 3 programs have not established higher subcutaneous maintenance doses than 2.4 mg weekly

Principal component analysis (PCA) was performed on the molecular data using MetaboAnalyst 6.0, which visually highlighted the clustering within groups and the separation between the tinnitus and control groups